Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Advanced Castration Resistant Prostate Cancer
NCT01682772Phase 2Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Jul 2012
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
olaparib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01682772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01682772.